clinicians preference when semaglutide is not suitable American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update Cardiovascular outcomes of semaglutide and

Titration schedule of Rybelsus is as follows: Formulation R1 (3 mg, 7 mg, 14 mg) Weeks 14 (Days 130): 3 mg once daily (This is the starting dose that may not be effective for glycemic control) Weeks 58 (Days 3160): 7 mg once daily Weeks 9 and onwards (Day 61+): Maintain 7 mg once daily if adequate control is achieved Increase to 14 mg once daily if additional glycemic control needed Formulation R2 (1.5 mg, 4 mg, 9 mg) Week 14 (Days 130): 1.5 mg once daily Week 58 (Days 3160): 4 mg once daily Week 9 onward (Day 61+): Maintain 4 mg once daily if adequate control is achieved or, Increase to 9 mg once daily if additional glycemic control is needed Why a conversion chart matters Liraglutide, semaglutide, and dulaglutide are GLP-1 agonists, but they have different active ingredients, indications, efficacy, and potencies

Do not rub the area around your incision

Originally developed as diabetes medications, semaglutide and tirzepatide are often prescribed for weight loss GLP-1 (glucagon-like peptide-1) receptor agonists are medications that mimic the GLP-1 hormone, which helps regulate blood sugar levels and appetite

Bring a copy of your prescription or a doctors note (not always required, but useful)